Morphological subtyping of acute myeloid leukemia with maturation (AML-M2): homogeneous pink-colored cytoplasm of mature neutrophils is most characteristic of AML-M2 with t(8;21)

Leukemia
H NakamuraM Tomonaga

Abstract

Morphologic and cytochemical features of 30 acute myeloid leukemia subtype M2 (AML-M2) patients with t(8;21) were compared with those of 50 AML-M2 patients without t(8;21). It was disclosed that irregular nuclear shape, Auer bodies, and at least 90% myeloperoxidase positivity in blast cells, and pseudo-Pelger-Huët anomaly of the nuclei and homogeneous pink-colored cytoplasm of mature neutrophils were observed in 90-100% of the t(8;21)+ patients. The percentages of patients showing these features were significantly (P < 0.01) lower in the t(8;21)- group. Among these morphological features, homogeneous pink-colored cytoplasm of mature neutrophils is most characteristic of t(8;21)+ AML-M2, because it was seen in 90% of the t(8;21)+ patients but in only 2% of the t(8;21)- patients. Conversely, pale-colored cytoplasm without any granules in mature neutrophils or dyserythropoietic features was observed in 84% of the t(8;21)- patients, but in none of the t(8;21)+ patients. These data suggest that it is possible to subtype AML-M2 patients morphologically by the recognition of homogeneous pink-colored or pale-colored cytoplasm of mature neutrophils and dyserythropoietic features. Thus, the morphologic subtyping of AML-M2 can be utilized...Continue Reading

Citations

Jan 28, 2009·Nature Chemical Biology·Jing-Ruey J YehRandall T Peterson
Aug 8, 1998·British Journal of Haematology·F FerraraL Del Vecchio
Mar 23, 1999·British Journal of Haematology·U CreutzigG Schellong
Feb 26, 2000·British Journal of Haematology·F PezzellaK C Gatter
Oct 31, 2002·European Journal of Haematology·Kinuyo KanedaMitsune Tanimoto
Apr 15, 2003·Leukemia & Lymphoma·Fernando Perez-ZincerMatt E Kalaycio
Apr 11, 2001·American Journal of Clinical Pathology·D A Arber
Feb 28, 2002·American Journal of Clinical Pathology·Daniel A ArberUNKNOWN International Workshop on Leukemia Karyotype and Prior Therapy
Jul 24, 2008·Journal of the National Cancer Institute. Monographs·Krzysztof Mrózek, Clara D Bloomfield
Jul 9, 2004·International Journal of Hematology·Keiki KawakamiIkuo Miura
Aug 12, 2003·Oncogene·Michael L GatzaSusan J Marriott
Jun 13, 2003·Oncogene·Anne-Sophie GabetEric Wattel
Sep 13, 2005·Oncogene·Susan J Marriott, Oliver John Semmes
Aug 11, 2000·Applied Immunohistochemistry & Molecular Morphology : AIMM·H W KorinM Younes
Jan 5, 2016·Leukemia & Lymphoma·Hans G DrexlerRoderick A F MacLeod
Apr 6, 2002·Clinics in Laboratory Medicine·Harold R SchumacherFermina Mazzella

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.